Browse All

Current Filters

CLEAR FILTER x

TITLE

Improvement in Patient-Reported Outcomes When Ubrogepant Is Administered During the Migraine Prodrome (Premonitory Phase): Results From the PRODROME Trial

A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine

Concentration QT Interval Modeling of Intranasally Administered Zavegepant in Healthy Subjects

Effects of Zavegepant and Concomitant Sumatriptan on Blood Pressure and Pharmacokinetics in Healthy Adult Participants